Evidence map›Paper›PMID 38064102›Full record

ArticleMolecular neurobiology2024

Oligodeoxynucleotide IMT504: Effects on Central Nervous System Repair Following Demyelination.

Patricia A Mathieu, Yim Rodriguez Sampertegui, Fernanda Elias, Alexis Silva Silva, María de Luján Calcagno, Ricardo López, Ana M Adamo

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Patricia A MathieuFacultad de Farmacia y Bioquímica, Departamento de Química Biológica, Universidad de Buenos Aires, Junín 956, C1113AAD, Buenos Aires, Argentina.
Yim Rodriguez SamperteguiFacultad de Farmacia y Bioquímica, Departamento de Química Biológica, Universidad de Buenos Aires, Junín 956, C1113AAD, Buenos Aires, Argentina.
Fernanda EliasInstituto de Ciencia y Tecnología Dr. César Milstein (CONICET-Fundación Pablo Cassará), Saladillo 2468, C1440FFX, Buenos Aires, Argentina.
Alexis Silva SilvaFacultad de Farmacia y Bioquímica, Departamento de Química Biológica, Universidad de Buenos Aires, Junín 956, C1113AAD, Buenos Aires, Argentina.
María de Luján CalcagnoFacultad de Farmacia y Bioquímica, Departamento de Fisicomatemática, Universidad de Buenos Aires, Junín 956, C1113AAD, Buenos Aires, Argentina.
Ricardo LópezImmunotech S.A., Buenos Aires, Argentina.
Ana M AdamoFacultad de Farmacia y Bioquímica, Departamento de Química Biológica, Universidad de Buenos Aires, Junín 956, C1113AAD, Buenos Aires, Argentina. anadamo@ffyb.uba.ar.ORCID http://orcid.org/0000-0002-9414-8182
Consejo Nacional de Investigaciones Científicas y Técnicas · ARUniversidad de Buenos Aires · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is an immune-mediated central nervous system (CNS) disease characterized by demyelination resulting from oligodendrocyte loss and inflammation. Cuprizone (CPZ) administration experimentally replicates MS pattern-III lesions, generating an inflammatory response through microgliosis and astrogliosis. Potentially remyelinating agents include oligodeoxynucleotides (ODN) with a specific immunomodulatory sequence consisting of the active motif PyNTTTTGT. In this work, the remyelinating effects of ODN IMT504 were evaluated through immunohistochemistry and qPCR analyses in a rat CPZ-induced demyelination model. Subcutaneous IMT504 administration exacerbated the pro-inflammatory response to demyelination and accelerated the transition to an anti-inflammatory state. IMT504 reduced microgliosis in general and the number of phagocytic microglia in particular and expanded the population of oligodendroglial progenitor cells (OPCs), later reflected in an increase in mature oligodendrocytes. The intracranial injection of IMT504 and intravenous inoculation of IMT504-treated B lymphocytes rendered comparable results. Altogether, these findings unveil potentially beneficial properties of IMT504 in the regulation of neuroinflammation and oligodendrogenesis, which may aid the development of therapies for demyelinating diseases such as MS.

Indexed as

Central Nervous SystemCuprizoneDemyelinating DiseasesMicrogliaOligodendrogliaOligodeoxyribonucleotidesAnimalsB-LymphocytesMaleRatsRats, Sprague-DawleyRats, WistarCuprizoneOligodeoxyribonucleotidesCuprizoneDemyelinationOligodeoxynucleotide IMT504Remyelination

Identifiers

PMID38064102
OpenAlexW4389483779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.